Ian is an independent consultant with expertise in regulatory and scientific aspects of nicotine and tobacco products. His consulting work encompasses clinical and behavioural studies of tobacco and nicotine products for regulatory submissions in the US and Europe, and he has a wealth of experience of both consumer goods and medicinal licensing submissions. His 16 years working in the Tobacco Harm Reduction arena has included roles as Senior Director of Clinical and Regulatory Affairs EMEA with JUUL Labs, Director of Tobacco Research with Celerion, and Principal Scientist and Head of Clinical Research at British American Tobacco. As well as his consulting, Ian is a Scientific Advisory Board Member with Qnovia, a medtech startup seeking authorisation for a novel NRT in the UK and the US, and is also an Independent Non-Exec Director with Advanced Inhalation Rituals (AIR), a global shisha manufacturer.

Professor Marewa Glover is one of New Zealand’s leading tobacco control researchers. She has worked on reducing smoking-related harm for 31 years. She is recognized internationally for her advocacy on tobacco harm reduction; and locally was a Finalist in the New Zealander of the Year Supreme Award in 2019 recognising her contribution to reducing smoking in NZ. In 2018, Dr Glover was appointed Tobacco Section Editor for the Harm Reduction Journal. In that year she also established the Centre of Research Excellence: Indigenous Sovereignty & Smoking, an international program of research aimed at reducing smoking-related harms among Indigenous peoples globally. The Centre’s research was funded with grants from the Foundation for a Smoke-Free World, Inc. (“FSFW”), a US nonprofit 501(c)(3) private foundation.

Sarah Cooney is a science engagement specialist, advises on harm reduction, science communication, and regulatory affairs. For over a decade at British American Tobacco, she spearheaded the company’s science engagement, helping pave the way for less-risky nicotine products. Sarah reshaped BAT’s publishing strategy, crafting award-winning reports to demystify reduced risk research. Her knack for making science accessible extends from boardrooms to public forums, bridging the gap between scientists, regulators, and the media. With editorial roles at Nature, Elsevier, and BioMedCentral, Sarah brings a wealth of publishing expertise. As a published scientist (with a BSc and an MSc from the University of Toronto) she understands the need for commitment to scientific accessibility and innovation.

George Hardie is Executive Director of tobacco harm reduction research for Dr Vince Clinical Research based in Kansas City. He has over 37 years in the science arena, with 23 years as a pre-clinical toxicologist where he holds an MSc in Applied Toxicology. He has an extensive background in the respiratory field where he was previously Head of Inhalation Toxicology for Pfizer. George migrated into clinical research 13 years ago and has participated in pharmaceutical studies with Astrazeneca and consumer healthcare studies with GSK. More recently he was the head of clinical research for British American Tobacco. He is highly regarded in the harm reduction field, where he has extensive knowledge and experience in all aspects of nicotine and tobacco harm reduction. George has contributed to multiple PMTA and MRTPA projects and has also authored/co-authored 20 peer-reviewed papers in tobacco harm reduction.

Colin Mendelsohn worked as a medical practitioner, academic and researcher in smoking cessation and tobacco harm reduction for 40 years. He is the Founding Chairman of the Australian Tobacco Harm Reduction Association and was a Conjoint Associate Professor in the School of Public Health and Community Medicine at the University of New South Wales. He was a member of the expert advisory group that develops the Royal Australian College of General Practitioners’ national smoking cessation guidelines. He is actively involved in teaching, writing, and advocating for tobacco harm reduction.